SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that Public Services and Procurement Canada (PSPC) has awarded SIGA a new contract for the procurement of oral TPOXX® (tecovirimat), an antiviral medication used to treat smallpox, on behalf of the Canadian Department of National Defence (CDND) through its Strategic Medical Countermeasures Program. The contract provides for the purchase of up to approximately $15 million by March 31, 2031, of which approximately $9 million represents firm commitments over the first three years of the contract and approximately $6 million is subject to option exercise by the CDND.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.